Gufic Biosciences Limited (BOM:509079)

Market Cap	42.24B +18.4%
Revenue (ttm)	9.81B +16.7%
Net Income	734.57M +18.7%
EPS	7.32 +18.7%
Shares Out	100.28M
PE Ratio	57.52
Forward PE	n/a
Dividend	0.10 (0.02%)
Ex-Dividend Date	Aug 28, 2026

Volume	15,061
Open	419.00
Previous Close	421.20
Day's Range	402.70 - 432.65
52-Week Range	267.50 - 447.85
Beta	-0.05
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Gufic Biosciences

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (P...

• Industry: Pharmaceutical Preparations
• Founded: 1970
• Employees: 1,484
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 509079

Financial Performance

In fiscal year 2026, Gufic Biosciences's revenue was 9.44 billion, an increase of 15.15% compared to the previous year's 8.20 billion. Earnings were 642.15 million, a decrease of -7.80%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 17, 2026

Data Sources Report a data error